CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced upcoming presentations at the American Society of Human Genetics (ASHG) 2021 Meeting, taking place October 18-22, 2021, and at the American Society of Nephrology’s (ASN) Kidney Week 2021, taking place November 4-7, 2021. Both meetings are being held virtually.
At ASHG, Goldfinch Bio will give an oral presentation showcasing insights revealed by its Kidney Genome Atlas (KGA). The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., DNA variations or polymorphisms) in patients with African ancestry. The KGA is a proprietary computational platform built in-house at Goldfinch Bio to identify genetic and environmental causes of kidney diseases in patient subsets and the associated biological targets for therapeutic intervention.
At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including:
- The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN) .1 GFB-887 is a podocyte-targeting, small molecule inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5), designed specifically to treat patients with kidney diseases characterized by an over-activation of the TRPC5-Rac1 pathway;
- The design of the ongoing Phase 1 clinical trial of GFB-024, a peripherally restricted cannabinoid 1 (CB1) inverse agonist monoclonal antibody intended to treat patients with severe insulin resistant DN and CB1 pathway overactivation;
- Additional data further supporting the use of the KGA to identify APOL1 and other genetic drivers of adult proteinuric kidney disease; and
- New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes.
“We are excited to share five presentations at ASHG and ASN, which together highlight the tremendous breadth and depth of genetic and clinical research ongoing at Goldfinch Bio,” said Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio. “In addition to advancing GFB-887 and GFB-024 through clinical development, we continue to uncover critical insights through our KGA, which incorporates multi-omic and clinical data from thousands of people to identify molecular and environmental causes of kidney disease, as well as potential targets for therapeutic intervention. We look forward to building on these insights as we continue to expand our portfolio and pursue our mission of delivering disease-modifying precision medicines that bring hope and renewed quality of life to many more people living with kidney diseases.”
Details of the presentations are as follows:
Presentation at the ASHG 2021 Virtual Meeting, October 18-22, 2021
Title: The Kidney Genome Atlas Reveals a Novel Locus on Chromosome 14 Associated with Adult Proteinuric Kidney Diseases
Platform Session Title: Global Perspectives and Initiatives for Large-Scale Genomics
Date and Time: Tuesday, October 19th at 5:00 PM ET
Presentations at ASN Kidney Week 2021, November 4-7, 2021
Abstract Title: TRACTION-2 Study: Safety and Efficacy Evaluation of GFB-887, a TRPC5 Channel Inhibitor, in Patients with DN, FSGS, or TR-MCD
Poster Number: INFO37
Abstract Title: Phase 1, Randomized, Controlled Trial of GBF-024 in Healthy Overweight and Obese Participants and in Participants with Type 2 Diabetes Mellitus
Poster Number: INFO13
Abstract Title: The Kidney Genome Atlas: A Resource to Understand APOL1 and Other Genetic Drivers of Adult Proteinuric Kidney Diseases
Poster Number: PO1326
Abstract Title: Identification of Kidney Disease Diagnoses in Patients with Diabetes by Biopsies and Electronic Health Records
Poster Number: PO0782
About Goldfinch Bio
Goldfinch Bio, Inc. is a clinical stage biotechnology company focused on delivering disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases. We aspire to save kidneys and end dialysis. Our precision medicine product engine allows us to discover, validate and drug novel targets that may allow us to better treat subsets of patients, within a heterogeneous kidney disease, based on common characteristics.. We have a robust pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet need, including two clinical-stage assets. In 2020, Goldfinch Bio was named one of Fierce Biotech’s “Fierce 15” companies. Visit us at www.goldfinchbio.com to learn more.
1 Patients diagnosed with treatment resistant minimal change disease, which is considered a subset of FSGS, are also being enrolled in the Phase 2 clinical trial.
Contacts
Goldfinch Bio:
Investors:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
Media:
Liz Melone
lmelone@goldfinchbio.com